1
|
Beavis AC, Dienger-Stambaugh K, Briggs K, Chen Z, Abraham M, Spearman P, He B. A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice. Vaccine 2024; 42:2347-2356. [PMID: 38443277 DOI: 10.1016/j.vaccine.2024.02.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Revised: 02/17/2024] [Accepted: 02/23/2024] [Indexed: 03/07/2024]
Abstract
Human immunodeficiency virus (HIV) infects and depletes CD4+ T-cells, resulting in Acquired Immunodeficiency Syndrome (AIDS) and death. Despite numerous clinical trials, there is no licensed HIV vaccine. The HIV envelope glycoprotein (env) is a major target for vaccine development, especially for the development of antibody-mediated protection. In this study, we used J paramyxovirus (JPV) as a viral vector to express HIV-env. We replaced the JPV small hydrophobic (SH) gene with HIV-env (rJPV-env). Intranasal rJPV-env immunization induced anti-HIV-gp120 IgG antibodies in mice. Furthermore, we examined the immunogenicity of homologous and heterologous prime/boost regimens with rJPV-env, parainfluenza virus 5 (rPIV5)-vectored HIV-env, and HIV-Gag-Env virus-like particles (VLPs). The rJPV-env/rPIV5-env heterologous prime/boost regimen induced the strongest humoral and cellular responses. Introducing a third dose of immunization, mice that received a viral-vectored prime had high levels of HIV-env-specific cellular responses, with group rJPV-env/rPIV5-env/VLP having the highest. Together, this work indicates that a heterologous combination of viral-vectored HIV-env vaccines and a HIV-Gag-Env VLP induces high levels of humoral and cellular responses against HIV in mice.
Collapse
Affiliation(s)
- Ashley C Beavis
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States of America
| | - Krista Dienger-Stambaugh
- Infectious Diseases Division, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH 45229, United States of America
| | - Kelsey Briggs
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States of America
| | - Zhenhai Chen
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States of America
| | - Mathew Abraham
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States of America
| | - Paul Spearman
- Infectious Diseases Division, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH 45229, United States of America
| | - Biao He
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States of America.
| |
Collapse
|
2
|
Gingerich MC, Nair N, Azevedo JF, Samanta K, Kundu S, He B, Gomes-Solecki M. Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year. NPJ Vaccines 2024; 9:33. [PMID: 38360853 PMCID: PMC10869809 DOI: 10.1038/s41541-023-00802-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 10/23/2023] [Indexed: 02/17/2024] Open
Abstract
Strategies for disease control are necessary to reduce incidence of Lyme Disease (LD) including development of safe vaccines for human use. Parainfluenza virus 5 (PIV5) vector has an excellent safety record in animals and PIV5-vectored vaccines are currently under clinical development. We constructed PIV5-vectored LD vaccine candidates expressing OspA from B. burgdorferi (OspAB31) and a chimeric protein containing sequences from B. burgdorferi and B. afzelii (OspABPBPk). Immunogenicity and vaccine efficacy were analyzed in C3H-HeN mice after prime-boost intranasal vaccination with live PIV5-OspAB31 or PIV5-OspABPBPk, subcutaneous (s.c.) vaccination with rOspAB31+Alum, and the respective controls. Mice vaccinated intranasally with live PIV5-AB31 or PIV5-ABPBPk had higher endpoint titers of serum antibody against OspAB31 at 6- and 12- months post vaccination, compared to mice vaccinated s.c. with rOspAB31. Neutralization activity of antibody was maintained up to 18-months post-immunization, with the response greater in live PIV5-delivered OspA vaccines, than that induced by s.c. rOspAB31. Challenge with infected ticks carrying 10-19 strains of B. burgdorferi performed at 4-, 9- or 15-months post-immunization showed increased breakthrough infections in mice vaccinated with s.c. rOspAB31 compared to intranasal PIV5-AB31 or PIV5-ABPBPk at 9- and 15-months, as determined by quantification of serologic antibodies to B. burgdorferi proteins as well as flaB DNA in tissues, and by visualization of motile B. burgdorferi in culture of tissues under dark field microscope. These findings indicate that immunization of mice with PIV5 delivered OspA generates immune responses that produce longer-lasting protection ( > 1 year) against tick-transmitted B. burgdorferi than a parenteral recombinant OspA vaccine.
Collapse
Affiliation(s)
- Maria Cristina Gingerich
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
- CyanVac, LLC, Athens, GA, USA
| | - Nisha Nair
- Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA
| | - Jose F Azevedo
- Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA
- Immuno Technologies, Inc., Memphis, TN, USA
| | - Kamalika Samanta
- Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA
- Merck & Co., West Point, PA, USA
| | - Suman Kundu
- Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA
- Immuno Technologies, Inc., Memphis, TN, USA
| | - Biao He
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
- CyanVac, LLC, Athens, GA, USA
| | - Maria Gomes-Solecki
- Department of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Tennessee, USA.
- Immuno Technologies, Inc., Memphis, TN, USA.
| |
Collapse
|
3
|
Vazquez T, Torrieri-Damard L, Pitoiset F, Levacher B, Vigneron J, Mayr L, Brimaud F, Bonnet B, Moog C, Klatzmann D, Bellier B. Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific T FH generation, high-quality antibodies and long-lasting mucosal immunity. Eur J Pharm Biopharm 2023; 191:124-138. [PMID: 37634825 DOI: 10.1016/j.ejpb.2023.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 08/23/2023] [Accepted: 08/24/2023] [Indexed: 08/29/2023]
Abstract
Mucosal surfaces serve as the primary entry points for pathogens such as SARS- CoV-2 coronavirus or HIV in the human body. Mucosal vaccination plays a crucial role to successfully induce long-lasting systemic and local immune responses to confer sterilizing immunity. However, antigen formulations and delivery methods must be properly selected since they are decisive for the quality and the magnitude of the elicited immune responses in mucosa. We investigated the significance of using particulate antigen forms for mucosal vaccination by comparing VLP- or protein- based vaccines in a mouse model. Based on a mucosal prime-boost immunization protocol combining (i) HIV- pseudotyped recombinant VLPs (HIV-VLPs) and (ii) plasmid DNA encoding HIV- VLPs (pVLPs), we demonstrated that combination of intranasal primes and intravaginal boosts is optimal to elicit both humoral and cellular memory responses in mucosa. Interestingly, our results show that in contrast to proteins, particulate antigens induce high-quality humoral responses characterized by a high breadth, long-term neutralizing activity and cross-clade reactivity, accompanying with high T follicular helper cell (TFH) response. These results underscore the potential of a VLP-based vaccine in effectively instigating long-lasting, HIV-specific immunity and point out the specific role of particulate antigen form in driving high-quality mucosal immune responses.
Collapse
Affiliation(s)
- Thomas Vazquez
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France
| | - Léa Torrieri-Damard
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France
| | - Fabien Pitoiset
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France
| | - Béatrice Levacher
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France
| | - James Vigneron
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France
| | - Luzia Mayr
- Université de Strasbourg, Fédération de médecine Translationnelle de Strasbourg, INSERM U1109, F-67000, France
| | - Faustine Brimaud
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France
| | - Benjamin Bonnet
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France
| | - Christiane Moog
- Université de Strasbourg, Fédération de médecine Translationnelle de Strasbourg, INSERM U1109, F-67000, France
| | - David Klatzmann
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France
| | - Bertrand Bellier
- Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France.
| |
Collapse
|
4
|
Beavis AC, Wee EGT, Akis Yildirim BM, Borthwick N, He B, Hanke T. Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa. Front Immunol 2023; 14:1186478. [PMID: 37529048 PMCID: PMC10390215 DOI: 10.3389/fimmu.2023.1186478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Accepted: 06/15/2023] [Indexed: 08/03/2023] Open
Abstract
Introduction The primary goal of this work is to broaden and enhance the options for induction of protective CD8+ T cells against HIV-1 and respiratory pathogens. Methods We explored the advantages of the parainfluenza virus 5 (PIV5) vector for delivery of pathogen-derived transgenes alone and in combination with the in-human potent regimen of simian adenovirus ChAdOx1 prime-poxvirus MVA boost delivering bi-valent mosaic of HIV-1 conserved regions designated HIVconsvX. Results We showed in BALB/c mice that the PIV5 vector expressing the HIVconsvX immunogens could be readily incorporated with the other two vaccine modalities into a single regimen and that for specific vector combinations, mucosal CD8+ T-cell induction was enhanced synergistically by a combination of the intranasal and intramuscular routes of administration. Discussion Encouraging safety and immunogenicity data from phase 1 human trials of ChAdOx1- and MVA-vectored vaccines for HIV-1, and PIV5-vectored vaccines for SARS-CoV-2 and respiratory syncytial virus pave the way for combining these vectors for HIV-1 and other indications in humans.
Collapse
Affiliation(s)
- Ashley C. Beavis
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States
| | - Edmund G. -T. Wee
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Belkis M. Akis Yildirim
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Nicola Borthwick
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Biao He
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States
| | - Tomáš Hanke
- The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
| |
Collapse
|
5
|
Tarrés-Freixas F, Aguilar-Gurrieri C, Rodríguez de la Concepción ML, Urrea V, Trinité B, Ortiz R, Pradenas E, Blanco P, Marfil S, Molinos-Albert LM, Barajas A, Pons-Grífols A, Ávila-Nieto C, Varela I, Cervera L, Gutiérrez-Granados S, Segura MM, Gòdia F, Clotet B, Carrillo J, Blanco J. An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses. NPJ Vaccines 2023; 8:51. [PMID: 37024469 PMCID: PMC10077320 DOI: 10.1038/s41541-023-00648-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2022] [Accepted: 03/17/2023] [Indexed: 04/08/2023] Open
Abstract
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineered to maximise the presence of antigen on the VLP surface. An HIV-1 gp41-derived protein (Min), including the C-terminal part of gp41 and the transmembrane domain, was fused to HIV-1 Gag. This resulted in high-density MinGag-VLPs. These VLPs demonstrated to be highly immunogenic in animal models using either a homologous (VLP) or heterologous (DNA/VLP) vaccination regimen, with the latter yielding 10-fold higher anti-Gag and anti-Min antibody titres. Despite these strong humoral responses, immunisation with MinGag-VLPs did not induce neutralising antibodies. Nevertheless, antibodies were predominantly of an IgG2b/IgG2c profile and could efficiently bind CD16-2. Furthermore, we demonstrated that MinGag-VLP vaccination could mediate a functional effect and halt the progression of a Min-expressing tumour cell line in an in vivo mouse model.
Collapse
Affiliation(s)
- Ferran Tarrés-Freixas
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | | | | | - Victor Urrea
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Benjamin Trinité
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Raquel Ortiz
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Edwards Pradenas
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Pau Blanco
- Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Sílvia Marfil
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Luis Manuel Molinos-Albert
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
- ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain
| | - Ana Barajas
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Anna Pons-Grífols
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Carlos Ávila-Nieto
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Ismael Varela
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
| | - Laura Cervera
- Grup d'Enginyeria Cel•lular i Bioprocessos, Department of Chemical, Biological and Environmental Engineering, Escola d'Enginyeria, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08913, Cerdanyola del Vallès, Catalonia, Spain
| | - Sònia Gutiérrez-Granados
- Grup d'Enginyeria Cel•lular i Bioprocessos, Department of Chemical, Biological and Environmental Engineering, Escola d'Enginyeria, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08913, Cerdanyola del Vallès, Catalonia, Spain
| | - María Mercedes Segura
- Grup d'Enginyeria Cel•lular i Bioprocessos, Department of Chemical, Biological and Environmental Engineering, Escola d'Enginyeria, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08913, Cerdanyola del Vallès, Catalonia, Spain
| | - Francesc Gòdia
- Grup d'Enginyeria Cel•lular i Bioprocessos, Department of Chemical, Biological and Environmental Engineering, Escola d'Enginyeria, Universitat Autònoma de Barcelona, Campus de Bellaterra, 08913, Cerdanyola del Vallès, Catalonia, Spain
| | - Bonaventura Clotet
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain
- University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Barcelona, Spain
| | - Jorge Carrillo
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain.
- Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, 08916, Barcelona, Spain.
- CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
| | - Julià Blanco
- IrsiCaixa AIDS Research Institute, Can Ruti Campus, 08916, Badalona, Catalonia, Spain.
- University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Barcelona, Spain.
- Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, 08916, Barcelona, Spain.
- CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
6
|
Zhang B, Mao H, Zhu H, Guo J, Zhou P, Ma Z. Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice. Front Microbiol 2023; 14:1136664. [PMID: 37007461 PMCID: PMC10063819 DOI: 10.3389/fmicb.2023.1136664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Accepted: 03/01/2023] [Indexed: 03/19/2023] Open
Abstract
Human immunodeficiency virus (HIV) induced AIDS causes a large number of infections and deaths worldwide every year, still no vaccines are available to prevent infection. Recombinant herpes simplex virus type 1 (HSV-1) vector-based vaccines coding the target proteins of other pathogens have been widely used for disease control. Here, a recombinant virus with HIV-1 gp160 gene integration into the internal reverse (IR) region-deleted HSV-1 vector (HSV-BAC), was obtained by bacterial artificial chromosome (BAC) technology, and its immunogenicity investigated in BALB/c mice. The result showed similar replication ability of the HSV-BAC-based recombinant virus and wild type. Furthermore, humoral and cellular immune response showed superiority of intraperitoneal (IP) administration, compared to intranasally (IN), subcutaneous (SC) and intramuscularly (IM), that evidenced by production of significant antibody and T cell responses. More importantly, in a prime-boost combination study murine model, the recombinant viruses prime followed by HIV-1 VLP boost induced stronger and broader immune responses than single virus or protein vaccination in a similar vaccination regimen. Antibody production was sufficient with huge potential for viral clearance, along with efficient T-cell activation, which were evaluated by the enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FC). Overall, these findings expose the value of combining different vaccine vectors and modalities to improve immunogenicity and breadth against different HIV-1 antigens.
Collapse
Affiliation(s)
- Beibei Zhang
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Ürümqi, Xinjiang, China
| | - Hongyan Mao
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Ürümqi, Xinjiang, China
| | - Hongjuan Zhu
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Ürümqi, Xinjiang, China
| | - Jingxia Guo
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Ürümqi, Xinjiang, China
| | - Paul Zhou
- Unit of Antiviral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
| | - Zhenghai Ma
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Ürümqi, Xinjiang, China
- *Correspondence: Zhenghai Ma,
| |
Collapse
|
7
|
Beavis AC, Li Z, Briggs K, Huertas-Díaz MC, Wrobel ER, Najera M, An D, Orr-Burks N, Murray J, Patil P, Huang J, Mousa J, Hao L, Hsiang TY, Gale M, Harvey SB, Tompkins SM, Hogan RJ, Lafontaine ER, Jin H, He B. Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2022:2022.06.07.495215. [PMID: 35702147 PMCID: PMC9196109 DOI: 10.1101/2022.06.07.495215] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Immunization with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has greatly reduced coronavirus disease 2019 (COVID-19)-related deaths and hospitalizations, but waning immunity and the emergence of variants capable of immune escape indicate the need for novel SARS-CoV-2 vaccines. An intranasal parainfluenza virus 5 (PIV5)-vectored COVID-19 vaccine CVXGA1 has been proven efficacious in animal models and blocks contact transmission of SARS-CoV-2 in ferrets. CVXGA1 vaccine is currently in human clinical trials in the United States. This work investigates the immunogenicity and efficacy of CVXGA1 and other PIV5-vectored vaccines expressing additional antigen SARS-CoV-2 nucleoprotein (N) or SARS-CoV-2 variant spike (S) proteins of beta, delta, gamma, and omicron variants against homologous and heterologous challenges in hamsters. A single intranasal dose of CVXGA1 induces neutralizing antibodies against SARS-CoV-2 WA1 (ancestral), delta variant, and omicron variant and protects against both homologous and heterologous virus challenges. Compared to mRNA COVID-19 vaccine, neutralizing antibody titers induced by CVXGA1 were well-maintained over time. When administered as a boost following two doses of a mRNA COVID-19 vaccine, PIV5-vectored vaccines expressing the S protein from WA1 (CVXGA1), delta, or omicron variants generate higher levels of cross-reactive neutralizing antibodies compared to three doses of a mRNA vaccine. In addition to the S protein, the N protein provides added protection as assessed by the highest body weight gain post-challenge infection. Our data indicates that PIV5-vectored COVID-19 vaccines, such as CVXGA1, can serve as booster vaccines against emerging variants.
Collapse
Affiliation(s)
- Ashley C. Beavis
- CyanVac LLC, Athens, Georgia, 30602
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Zhuo Li
- CyanVac LLC, Athens, Georgia, 30602
| | - Kelsey Briggs
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - María Cristina Huertas-Díaz
- CyanVac LLC, Athens, Georgia, 30602
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Elizabeth R. Wrobel
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | | | - Dong An
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Nichole Orr-Burks
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Jackelyn Murray
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | | | - Jiachen Huang
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Jarrod Mousa
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Linhui Hao
- Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, Washington
| | - Tien-Ying Hsiang
- Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, Washington
| | - Michael Gale
- Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, Washington
| | - Stephen B. Harvey
- Animal Resources, University of Georgia, Athens, Georgia; Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - S. Mark Tompkins
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Robert Jeffrey Hogan
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Eric R. Lafontaine
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| | - Hong Jin
- CyanVac LLC, Athens, Georgia, 30602
| | - Biao He
- CyanVac LLC, Athens, Georgia, 30602
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia
| |
Collapse
|
8
|
COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. J Microbiol 2022; 60:321-334. [PMID: 35157221 PMCID: PMC8853094 DOI: 10.1007/s12275-022-1621-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 12/30/2021] [Accepted: 12/31/2021] [Indexed: 12/11/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), has led to many cases and deaths worldwide. Therefore, a number of vaccine candidates have been developed to control the COVID-19 pandemic. Of these, to date, 21 vaccines have received emergency approval for human use in at least one country. However, the recent global emergence of SARS-CoV-2 variants has compromised the efficacy of the currently available vaccines. To protect against these variants, the use of vaccines that modulate T cell-mediated immune responses or innate immune cell memory function, termed trained immunity, is needed. The major advantage of a vaccine that uses bacteria or viral systems for the delivery of COVID-19 antigens is the ability to induce both T cell-mediated and humoral immune responses. In addition, such vaccine systems can also exert off-target effects via the vector itself, mediated partly through trained immunity; compared to other vaccine platforms, suggesting that this approach can provide better protection against even vaccine escape variants. This review presents the current status of the development of COVID-19 vaccines based on recombinant viral and bacterial delivery systems. We also discuss the current status of the use of licensed live vaccines for other infections, including BCG, oral polio and MMR vaccines, to prevent COVID-19 infections.
Collapse
|